MedTrace Logo

Dietary Nucleotides and Ribose on Muscle Fuel Utilisation

NCT03659890 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2020-03-26

No results posted yet for this study

Summary

Nucleotides are the building blocks for a variety of molecules, including ATP, which is broken down in the skeletal muscle cells to provide fuel for exercise. Nucleotides can be obtained from the diet, and produced or salvaged by the body. Though nucleotides provide the building blocks for ATP, the sugar ribose has been suggested to be rate limiting for synthesising ATP.

Previous studies have shown a decrease in ATP levels in the muscle after intense exercise, and this is linked to fatigue. Other studies have also reported benefits of nucleotide and/or ribose supplementation on exercise performance. However, any potential link between ATP metabolism and exercise performance has not been explored.

This study will look at the effects of nucleotide and nucleotide-ribose supplementation in fuel utilisation and performance in skeletal muscle during endurance exercise.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Low nucleotide

2 week, twice daily, supplementation with a nucleotide-depleted mycoprotein drink, with added dextrose

DIETARY_SUPPLEMENT

High nucleotide

2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added dextrose

DIETARY_SUPPLEMENT

High nucletide + Ribose

2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added ribose

Sponsors & Collaborators

  • University of Exeter

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-28
Primary Completion
2020-02-02
Completion
2020-02-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03659890 on ClinicalTrials.gov